Contributions of human cytochrome P450 enzymes to glyburide metabolism

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 4, 2010, Pages 228-242

  Zhou, Lin ^a,b   Naraharisetti, Suresh B ^a,b   Liu, Li ^a   Wang, Honggang ^a   Lin, Yvonne S ^a   Isoherranen, Nina ^a   Unadkat, Jashvant D ^a   Hebert, Mary F ^a   Mao, Qingcheng ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

CYP2C9; CYP3A4; Glyburide; Human CYP enzymes; In vitro metabolism

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLIBENCLAMIDE; KETOCONAZOLE; METHOXSALEN; MONTELUKAST; OMEPRAZOLE; QUININE; SULFAPHENAZOLE; THIOTEPA; ANTIDIABETIC AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A; ISOENZYME;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; MICHAELIS CONSTANT; PROTEIN EXPRESSION; METABOLISM;

CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; MICROSOMES, LIVER;

EID: 77955286114     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.706     Document Type: Article

References (39)

1. Feldman JM. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 1985; 5: 43-62.
2. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-1138.
3. Moore TR. Glyburide for the treatment of gestational diabetes. A critical appraisal. Diabetes Care 2007; 30 (Suppl 2): S209-S213.
4. Hebert MF, Ma X, Naraharisetti SB et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 2009; 85: 607-614.
5. Zharikova OL, Ravindran S, Nanovskaya TN, Hill RA, Hankins GD, Ahmed MS. Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon. Biochem Pharmacol 2007; 73: 2012-2019.
6. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibencla-mide) metabolites in humans. Diabetes Care 1994; 17: 1026-1030.
7. Hellman B, Sehlin J, Taljedal IB. Glibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cellrich pancreatic islets. Acta Endocrinol (Copenh) 1984; 105: 385-390.
8. Sartor G, Melander A, Schersten B, Wahlin-Boll E. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 1980; 18: 17-22. (Pubitemid 10202722)
9. Huupponen R, Viikari J, Saarimaa H. Chlorpro-pamide and glibenclamide serum concentrations in hospitalized patients. Ann Clin Res 1982; 14: 119-122.
10. Matsuda A, Kuzuya T, Sugita Y, Kawashima K. Plasma levels of glibenclamide in diabetic patients during its routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res 1983; 15: 425-428.
11. Ferner RE, Chaplin S. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 1987; 12: 379-401.
12. Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet 1989; 16: 100-128.
13. Cavallari LH, Limdi NA. Warfarin pharmacogenomics. Curr Opin Mol Ther 2009; 11: 243-251.
14. Kirchheiner J, Brockmoller J, Meineke I et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 2002; 71: 286-296. (Pubitemid 34311458)
15. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-332.
16. Yin OQ, Tomlinson B, Chow MS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 2005; 78: 370-377.
17. Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004; 34: 415-427. (Pubitemid 38901452)
18. Zharikova OL, Fokina VM, Nanovskaya TN et al. Identification of the major human hepatic and placental enzymes responsible for the biotrans-formation of glyburide. Biochem Pharmacol 2009; 78: 1483-1490.
19. Hill RA, Rudra S, Peng B et al. Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem 2003; 11: 2099-2113.
20. Thummel KE, Kharasch ED, Podoll T, Kunze K. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993; 21: 350-357.
21. Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280: 730-738.
22. Walsky RL, Obach RS, Gaman EA, Gleeson JP, Proctor WR. Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 2005; 33: 413-418.
23. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998; 26: 207-215.
24. Wandel C, Kim RB, Guengerich FP, Wood AJ. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab Dispos 2000; 28: 895-898.
25. Rae JM, Soukhova NV, Flockhart DA, Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 2002; 30: 525-530.
26. Sai Y, Dai R, Yang TJ et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000; 30: 327-343.
27. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25: 261-270.
28. Ravindran S, Zharikova OL, Hill RA, Nanovskaya TN, Hankins GD, Ahmed MS. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol 2006; 72: 1730-1737.
29. Dixit V, Hariparsad N, Desai P, Unadkat JD. In vitro LC-MS cocktail assays to simultaneously determine human cytochrome P450 activities. Biopharm Drug Dispos 2007; 28: 257-262.
30. Zhou L, Naraharisetti SB, Wang H, Unadkat JD, Hebert MF, Mao Q. The breast cancer resistance protein (Bcrp1 / Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 2008; 73: 949-959.
31. Naraharisetti SB, Kirby BJ, Hebert MF, Easterling TR, Unadkat JD. Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 860: 34-41.
32. Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 2002; 30: 831-837.
33. Nakai D, Kumamoto K, Sakikawa C, Kosaka T, Tokui T. Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method. J Pharm Sci 2004; 93: 847-854.
34. Yasar U, Lundgren S, Eliasson E et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 2002; 299: 25-28.
35. Jonsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17:142-145.
36. Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 1990; 29: 673-684.
37. Hebert MF, Easterling TR, Kirby B et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 2008; 84: 248-253.
38. Na-Bangchang K, Manyando C, Ruengweerayut R et al. The pharmacokinetics and pharmacody-namics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol 2005; 61: 573-582.
39. McGready R, Stepniewska K, Seaton E et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 2003; 59: 553-557.